Delivering Chemotherapy Drugs Directly into Cancer Cells While Minimizing Harm
Delivering Chemotherapy Drugs Directly into Cancer Cells While Minimizing Harm Ren Homan, Ph.D., Co-Founder of Peptinovo Biopharma and Steve Tokarz, CEO of Peptinovo Biopharma
Peptinovo Biopharma’s Targeted Cancer Drug Platform Approved for Clinical Trials
Peptinovo Biopharma, an Ann Arbor–based biotechnology company pioneering targeted cancer therapies through its first-of-its-kind proprietary PALM™ nanotechnology, today announced it has received approval to initiate its first human clinical trials in Australia. The milestone clears the way for the company to begin enrolling cancer patients in the coming months.
Peptinovo Biopharma in Collaboration with Chemelectiva Announces Breakthrough Manufacturing Innovation for Targeted Chemotherapy
Peptinovo Biopharma, an Ann Arbor-based biotechnology company pioneering targeted cancer therapies through its proprietary PALM™ nanotechnology, today announced a major manufacturing and intellectual property milestone achieved in collaboration with Chemelectiva Srl, an Italian specialty pharmaceutical chemistry company. The breakthrough significantly advances Peptinovo’s proprietary prodrug platform for targeted chemotherapy delivery
Peptinovo Biopharma Partners with Alcami to Advance Novel Cancer Nanotechnology and Enable Global Distribution
Peptinovo Biopharma, an Ann Arbor–based biotechnology company pioneering targeted cancer therapies through its proprietary PALM™ nanotechnology, today announced a strategic partnership with Alcami Corporation, a leading U.S.-based contract development and manufacturing organization (CDMO), to advance the company’s novel nanotechnology platform toward commercial readiness and worldwide distribution.
Peptinovo Biopharma Selects Ardena as Manufacturing Partner to Advance Its Novel Cancer Nanotechnology Toward Clinical Trials
Peptinovo Biopharma, a biotechnology company pioneering targeted cancer therapies through its proprietary PALM™ nanotechnology, announced a strategic manufacturing partnership with Ardena, a specialist pharmaceutical contract development and manufacturing organization (CDMO) and bioanalytical contract research organization (CRO) enabling precision medicines and other complex therapies. Ardena will manufacture Peptinovo’s cancer drug-delivery nanotechnology for the company’s planned launch of human clinical trials by year end.